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The aim of study is to investigate the expression of the LHCG receptor in the human penis to 
see, if the LH effects are possible in the spongious and cavernous tissue of the penis. The num-
ber of men with erection disturbances increases significantly simultaneously with the elevated 
LH concentrations between 40 and 70 years. It is possible that the elevated LH concentrations 
may influence locally the erectile mechanisms. The precondition for this is the expression of 
LHCG receptors in the penis. Penile tissue was obtained from three patients undergoing total 
or partial penectomy due to a rectal cancer with secondary penile metastasis or squamous cell 
carcinoma of the penis. Immunohistochemistry was used for the detection of the LHCG recep-
tor. Positive immunoreaction for LHCG receptors was discovered in the endothelial cells of 
cavernous spaces in the corpus cavernosum and corpus spongiosum penis, also in the endothe-
lial cells of the capillary walls in all patients. Our results show that LHCG receptor is expressed 
in the spongious and cavernous tissue of the human penis. This finding suggests that LH can 
affect the spongious and cavernous tissue in human and play a role in the development of erec-
tile dysfunction among the aging men. 
 
Keywords: corpus cavernosum penis; corpus spongiosum penis; erectile disturbances; lutein-
izing hormone  
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Introduction 
The luteinizing hormone/choriogonadotropin receptor (LHCGR) belongs to the group of gly-
coprotein hormone receptors (GpHRs) [2, 8]. LH and hCG bind both to the LHCGR [35]. Sim-
ilarly to other G-protein coupled receptors, LHCGR is anchored within the cell membrane by 
seven transmembrane domains [38, 39]. Locating on the short arm of chromosome 2 (2p21) the 
human LHCGR gene consists of 11 exons and 10 introns, complemented by the primate-spe-
cific exon 6A [3, 27]. Inactivating and disease-causing mutations of the LHCGR gene have 
been described [28, 5]. Besides Leydig cells [23, 14] the LHCGR is expressed by many cell 
types, including the corpus luteal cells of the ovary [6], the decidua [30], the myometrium [33], 
the uterine vasculature [42], the smooth muscle and endothelial cells of umbilical arteries and 
vein [37], the embryonic stem cells [16], the trophoblasts [34], and some of the brain cells [6, 
11]. In the testis, LHGCRs are expressed during the fetal life, postnatally, at puberty, and also 
throughout adult life [13]. This makes it possible for the pituitary LH to stimulate testosterone 
production in Leydig cells during the normal male embryogenesis and also after puberty, lead-
ing to induction and maintenance of secondary sexual features, including penile growth.  
It has been previously shown that LHCGR is present in the mouse penis [26]. Positive immu-
noreaction was found in the nuclei of urethral epithelium, in the endothelial cells of cavernous 
spaces in the corpus spongiosum and corpus cavernosum penis. The expression of LHCG re-
ceptors in the mouse penis was also confirmed by western blot analyses and by the quantitative 
RT-PCRs [26]. 
As it is predicted that by 2025 roughly 322 million men are affected world-wide by erectile 
dysfunction [1] and as hypogonadism[19, 32] and subclinical hypogonadism ( LH > 6.0 IU ⁄ L 
and T > 9.8 nmol/L [15, 28] and 31% of 41–50, 51–60 and 61–70-year-old men, respectively 
[22]; LH > 8.0 IU/L and T > 12 nmol/l [15]), where the LH serum levels are higher than nor-
mally, are a frequent problem in the middle- and older-aged men, who also often have erectile 
dysfunction, it should be asked, whether the high LH levels of the aging men are involved in 
the development of impotence directly through actions on the penile tissue. As the  prerequisite 
for this would be the expression of LHCG receptors in the penile tissue, the expression of 
LHCG receptors was studied in the human penile tissue in the present study to see, if LH action 
in this tissue is possible and if the age-associated increase in the LH levels could be involved 
in erectile dysfunction.    
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Materials and methods 
Penile tissue was obtained from three patients undergoing partial or total penectomy either due 
to rectal cancer or squamous cell carcinoma of the penis. The patients were being treated at the 
Tampere University Hospital. 
Two patients (66-year-old and 64-year-old) were undergoing total penectomy due to rectal can-
cer with secondary penile metastasis and one 83-year-old patient with squamous cell carcinoma 
of the penis was undergoing partial penectomy.  
Samples from corpus cavernosum and corpus spongiosum penis were fixed in 4% formalin 
overnight at 4 ˚C. After fixation, the samples were stored in 70% ethanol until embedding in 
paraffin. 
Immunohistochemistry 
The 5 µm sections were cut, deparaffinized and treated with 0.9% H2O2 to inactivate endoge-
nous peroxidase. The sections were then treated with Dako REAL Antibody Diluent (S2022; 
Dako Denmark A/S, Glostrup, Denmark) to block non-specific binding. After blocking, the 
sections were incubated with the rabbit polyclonal antibody to luteinizing hormone receptor 
(LHCGR) (C-term) (SP4594P, Acris Antibodies) overnight at 4 °C.  
The immunoaffinity-purified antibody used was validated by Kokk et al. (2011) in the mouse 
using immunohistochemistry, western blotting and qRT-PCR showing LHR antigens at M(r) = 
97.4 and 78 kD. The usability of the antibody was confirmed by specific expression of LHR in 
the same spongious tissue in qRT-PCR. In the present study, the difficulty in obtaining human 
penile tissue prevented repeating the same with the human tissue, but the earlier validation of 
the antibody using several methods in the mouse together with the information of the producer’s 
data sheet (Acris Antibodies) about the usability of the antibody in immunohistochemistry in 
the human tissue was considered as sufficient for the present study.  
Primary antibody dilution was 1:500. Visualization of the primary antibody was performed 
using the commercial kit Dako REAL™ EnVision™ Detection System, Peroxidase/DAB+, 
Rabbit/Mouse (K5007; Dako Denmark A/S, Glostrup, Denmark). Washing steps in-between 
were done in phosphate buffered saline (PBS) which contained 0.07% Tween 20 as the deter-
gent. Toluidine blue (Applichem, Darmstadt, Germany) was used for background staining. No 
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Positive immunoreaction for LHCG receptors in the endothelial cells of cavernous spaces both 
in the corpus spongiosum penis (Figure 1A) and the corpus cavernosum penis (Figure 1B) was 
found in tissue samples of all patients. Positive immunoreaction was also present in the endo-
thelial cells of capillary walls (Figure 1C). 




Fig. 1. Expression of LHCG receptors in the human penis. Positive cells are pointed by arrows. 
Note the presence of LHCG receptors in the endothelial cells of the cavernous spaces in corpus 
spongiosum penis (A) and corpus cavernosum penis (B). Positive immunoreaction is also pre-
sent in the endothelial cells of the capillary wall (C). No positive cells were present in negative 
controls (D). All photographs were taken using the x100 objective. The scalebar is on the lower 
right corner of the figures.   
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Discussion 
The present results show that besides the mouse penis LHCGR is also expressed in the human 
penis. At present, it is not yet clear, what functions LHCGR may have in the penis, but it is 
possible that the aging-associated increased serum LH concentrations [22] regulate the function 
of the endothelial cells of the corpus spongiosum and cavernosum expressing the LHCGR. This 
finding is supported by the observations of Yu et al. (2017), who confirmed the influence of 
increased age and LH on the aging male symptoms and on the 5-item version of the interna-
tional index of erectile function scores [43]. 
Erectile dysfunction as an inability to achieve normal erection and to keep it for the sufficient 
time can be the result of many health conditions, including neurologic, psychogenic, vascular, 
urogenital and hormonal abnormalities. Erectile dysfunction can also develop post-traumati-
cally and after surgery [9]. Potency disturbances possibly also have a genetic dimension, as e.g. 
expression of the DM1 protein kinase (DMPK) gene may be associated with many age-related 
signs, including hypogonadism and erectile disorders and there can be CTG repeat expansions 
in this gene affecting its function [4]. 
 Until now it has not been suggested that LH could directly affect the penile tissue of the aging 
men. This is however a serious alternative after it has been demonstrated that LHCG receptors 
are expressed in the endothelium of the spongious tissue of the penis in two species, the mouse 
[26] and the human; that a significant proportion of the aging men are in a subclinical or clinical 
hypogonadism with their LH concentrations in the serum elevated [10, 15, 22, 29]; and that LH 
influences the 5-item version of the international index of erectile function scores [43]. Func-
tional tests would be needed to study this hypothesis further.  
However, the late-onset hypogonadism may be a result of testicular failure or hypothalamic-
pituitary failure. The first form is bound up with low T and high luteinizing hormone levels. 
The second form is often related with overweight, but also with chronic diseases (the metabolic 
syndrome, hypertension, inflammatory arthritis, diabetes, chronic obstructive lung disease, 
heart failure etc.). The latter form is more common and shows low T and low or inappropriately 
normal LH [21]. According to Bunch et al.(2002), 225 testosterone deficient patients ( testos-
terone < 300ng/dl ) were found amongst the erectile dysfunction patients of their study and in 
29 of them (12.9 %) secondary hypogonadism based on a LH < 13 mlU/ml  was diagnosed [7]. 
These findings may indicate that the suggested direct effect of high LH on the penile tissue is 
not the only factor involved.  
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If both of the above mentioned forms of hypogonadism are equally associated with erectile 
dysfunction, is not known, but the present evidence together with the data of Yu et al. (2017, 
[43]) and Härkönen et al. (2003, [22) would suggest that high LH associated with clinical or 
subclinical primary hypogonadism of the aging male might possibly affect the penile endothe-
lial cells through the penile LHCGR and thus perhaps be a factor in the development of potency 
disturbances.  
 
In fact, in our earlier preliminary studies, this suggestion was supported by the observation that 
there was a statistically significant positive correlation between s-LH and the reported severity 
of decreased potency among 61-70-year-old men (p < 0.05, n = 90; the subjects graded their 
potency disturbance in a form interview before their LH and T levels were measured; [36]) and 
between s-LH and the reported severity of decreased frequency of morning erections in the 
same age group (p < 0.05, n = 90; [36]), but not among the 40-50-years-old or the 51-60-years 
old men. Also these earlier observations together with the findings of Yu et al. (2017 [43]) and 
the  present observations on the protein level LHCGR expression in the human penile endothe-
lium would indicate that subclinical or clinical hypogonadism characterized by elevated LH 
may possibly affect the penile function as suggested. However, while in the this far published 
genome wide association studies for erectile dysfunction, LH or LHCGR have not been re-
ported to be associated with erectile dysfunction [24, 20, 25], the FSH receptor has been [24] 
and as FSH increases with age like LH [32], it is possible that the increased FSH leads to erectile 
dysfunction instead or together with the increased LH, but at present, there is no data about 
FSH receptor expression in the penile tissue available.  
 
On the basis of the present knowledge, it can not be excluded that the aging-associated high LH 
levels of the male may have an effect on the endothelial cells of the spongious tissue through 
the LHCG receptors. Furthermore, as the LH and FSH receptors belong to the same superfamily 
of G-coupled glycoprotein hormone receptors [2,8] with the same α subunit and 40 % homology 
in the sequence of the ectodomains and 70 % homology in the functionally significant serpen-
tine domain of the genes of their β subunits [12] and as it is known that chorionic gonadotrophin 
in high concentrations can inapproriately stimulate the FSH receptor [31] and the TSH receptor 
[18], it is not excluded that the same may also occur vice versa, if the FSH or the TSH levels 
are high. The role of high FSH may be strengthened by the observations of  Santi et al. (2017, 
[40]), who reported a case of an atypical giant pituitary adenoma secreting follicle-stimulating 
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hormone in 55 year-old patient with fatigue, loss of libido and erectile disorder. It has also been 
reported that the wild-type LHCG receptors and the wild-type FSH receptors can form dimers 
[41], suggesting a more complex interaction between these two G-protein-coupled transmem-
brane receptors. However, the present results demonstrate that the high circulating LH of the 
aging male could possibly bind to the LHCG receptor expressed by the penile endothelial cells 
and perhaps induce some effects in their functions. Experimental arrangements to test this pos-
sibility should be organized in the future.  
 
Last but not the least, it should remembered that the postmenopausal women as well as women 
approaching ovulation have high serum LH levels and the pregnant women have high levels of 
serum hCG, suggesting that high female LH or hCG concentrations in the vaginal excretions 
might bind to the penile LHCG receptors, thus possibly affecting the penile endothelial cell 
functions. However, the LHCG receptors are expressed by cells deep inside the penile tissue, 
suggesting that LH or hCG in the vaginal excretions may not reach these cells without active 
transport at some point between the penile surface and the spongious tissue [17]. Further studies 
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